These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 2676044

  • 1. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
    Spitzer TR, Cottler-Fox M, Torrisi J, Cahill R, Greenspan A, Lynch M, Deeg HJ.
    Bone Marrow Transplant; 1989 Sep; 4(5):559-65. PubMed ID: 2676044
    [Abstract] [Full Text] [Related]

  • 2. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
    Wu DP, Milpied N, Moreau P, Mechinaud-Lacroix F, Mahe B, Le Tortorec S, Rapp MJ, Bourdin S, Mahe JM, Harousseau JL.
    Bone Marrow Transplant; 1994 Nov; 14(5):751-7. PubMed ID: 7889008
    [Abstract] [Full Text] [Related]

  • 3. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
    Hänel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hänel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR.
    Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
    [Abstract] [Full Text] [Related]

  • 4. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [Abstract] [Full Text] [Related]

  • 5. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
    Vaughan WP, Dennison JD, Reed EC, Klassen L, McGuire TR, Sanger WG, Kumar PP, Warkentin PI, Gordon BG, Bierman PJ.
    Bone Marrow Transplant; 1991 Dec; 8(6):489-95. PubMed ID: 1790429
    [Abstract] [Full Text] [Related]

  • 6. Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation.
    Geller RB, Myers S, Devine S, Larson RA, Williams SF, Park CL, O'Toole K, Chandler C, Topper RL.
    Bone Marrow Transplant; 1992 Jan; 9(1):41-7. PubMed ID: 1543948
    [Abstract] [Full Text] [Related]

  • 7. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy.
    Kröger N, Hoffknecht M, Hänel M, Krüger W, Zeller W, Stockschläder M, de Wit M, Weh HJ, Kabisch H, Erttmann R, Zander AR.
    Bone Marrow Transplant; 1998 Jun; 21(12):1171-5. PubMed ID: 9674847
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bone marrow transplantation for advanced acute leukemia: a pilot study of high-energy total body irradiation, cyclophosphamide and continuous infusion etoposide.
    Bostrom B, Weisdorf DJ, Kim T, Kersey JH, Ramsay NK.
    Bone Marrow Transplant; 1990 Feb; 5(2):83-9. PubMed ID: 2107007
    [Abstract] [Full Text] [Related]

  • 12. New conditioning regimens for high risk marrow transplants.
    Jones RJ, Santos GW.
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():15-7. PubMed ID: 2627618
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
    Kamani N, August CS, Bunin N, Leahey A, Bayever E, Goldwein J, Zusman J, Evans AE, Angio GD.
    Bone Marrow Transplant; 1996 Jun; 17(6):911-6. PubMed ID: 8807093
    [Abstract] [Full Text] [Related]

  • 17. Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation.
    Crilley P, Topolsky D, Styler MJ, Bernstein E, Resnick K, Mullaney R, Bulova S, Brodsky I, Marks DI.
    Bone Marrow Transplant; 1995 Mar; 15(3):361-5. PubMed ID: 7599559
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pulmonary complications of bone marrow transplantation: a comparison of total body irradiation and cyclophosphamide to busulfan and cyclophosphamide.
    Hartsell WF, Czyzewski EA, Ghalie R, Kaizer H.
    Int J Radiat Oncol Biol Phys; 1995 Apr 30; 32(1):69-73. PubMed ID: 7536723
    [Abstract] [Full Text] [Related]

  • 20. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Kabisch H, Jaburg N, Löliger C, Krüll A, Zander AR.
    Bone Marrow Transplant; 2001 Feb 30; 27(4):349-54. PubMed ID: 11313663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.